Global Tourette Syndrome Treatment Market Report 2023-2034: Antipsychotics Remain the Mainstay of Treatment, Emergence of Non-Antipsychotics and Full-Spectrum Treatment Alternatives Present New Potential
January 25, 2024 11:38 ET
|
Research and Markets
Dublin, Jan. 25, 2024 (GLOBE NEWSWIRE) -- The "Global Tourette Syndrome Treatment Market" report has been added to ResearchAndMarkets.com's offering. The relentless pursuit of innovation in...
Tourette Syndrome Clinical Trial Research Analysis Report 2023: Breakdown by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries
August 18, 2023 06:38 ET
|
Research and Markets
Dublin, Aug. 18, 2023 (GLOBE NEWSWIRE) -- The "Tourette Syndrome Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2023 Update"...
SciSparc Ltd. Announces Additional Positive Results for the Cocaine Addiction Treatment of its Psychedelic-based Pharma Collaboration with Clearmind Medicine Inc.
August 24, 2022 07:30 ET
|
SciSparc Ltd
Results indicate significant decrease in cocaine craving in a sub-group that received the treatment TEL AVIV, Israel, Aug. 24, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC), a...
Scisparc Announces the Full Exercise of Pre-Funded Warrants
August 19, 2022 06:45 ET
|
SciSparc Ltd
The pre-funded warrants were issued as part of the $10 million private placement from June 2022 TEL AVIV, Israel, Aug. 19, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or...
SciSparc will Deposit $1 million in Escrow for its Intention to Enter Into an Agreement to Acquire American Food Supplements and Cosmetics Brand
August 18, 2022 08:15 ET
|
SciSparc Ltd
The Company has signed an escrow agreement following the signing of a non-binding letter of intent and will be deposit a $1.0 million as an initial intention to enter into a definitive acquisition...
SciSparc Signs a Non- Binding Letter of Intent to Acquire American Food Supplements and Cosmetics Brand in Approximately $20 Million Deal
August 15, 2022 08:30 ET
|
SciSparc Ltd
The Letter of Intent contemplates the purchasing of a brand, trademark and Amazon.com seller account, a management agreement, a U.S. distribution agreement and an option to expand to new territories ...
SciSparc Signs Clinical Trial Agreement with Yale University to Conduct its Phase IIb Trial in Tourette Syndrome
August 01, 2022 09:30 ET
|
SciSparc Ltd
The addition of a U.S. site will allow SciSparc to accelerate trial recruitment and further development of novel treatments for patients in need TEL AVIV, Israel, Aug. 01, 2022 (GLOBE NEWSWIRE)...
SciSparc Announces Expanding its Clinical Operations to Include a U.S. Site Towards its Phase IIb Trial with its Proprietary SCI-110 for the Treatment of Tourette Syndrome
July 08, 2022 08:30 ET
|
SciSparc Ltd
TEL AVIV, Israel, July 08, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies...
SciSparc's JV MitoCareX Bio Launches its Advanced New Laboratory Facility
July 07, 2022 08:30 ET
|
SciSparc Ltd
The new facility will serve the JV’s development of potential cancer drugs TEL AVIV, Israel, July 07, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a...
SciSparc Board of Directors to Promote Buyback Program of up to $1 Million
July 06, 2022 08:30 ET
|
SciSparc Ltd
TEL AVIV, Israel, July 06, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the “Company” or “SciSparc”), a specialty, clinical-stage pharmaceutical company focusing on the development of...